Multiplex Cancer Biomarker Panel for Noninvasive Serum Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnosis methods, particularly for prostate cancer, are invasive, inaccurate, and prone to false negatives, necessitating improved biomarkers for early detection and diagnosis.
Innovation Solution
A diagnostic composition and kit utilizing agents that measure the expression levels of PKCα, IGFI, KLK2, and/or TRPM8 proteins or mRNAs, combined with a lateral flow assay strip, enabling simultaneous multiplex detection of various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional tissue biopsy methods are used for cancer diagnosis, then detection capability is achieved, but patient discomfort and invasiveness increase
Solution Approach 1:
The patent replaces mechanical tissue biopsy procedures with a biochemical detection system. Instead of physically extracting and examining tissue samples through needles and surgical instruments, the invention uses antibodies and detection reagents to identify cancer markers in bodily fluids, thereby eliminating the need for invasive mechanical procedures while maintaining diagnostic capability
Solution Approach 2:
The patent introduces antibodies as intermediary substances that mediate between the cancer markers in patient samples and the detection system. These antibodies specifically bind to cancer-related proteins or mRNAs, enabling indirect detection of cancer presence without direct tissue manipulation, thus reducing patient discomfort while preserving detection accuracy
2Productivity
If PSA-based screening methods are used for prostate cancer diagnosis, then screening coverage is achieved, but diagnostic accuracy decreases due to false positives and negatives
Solution Approach 1:
The patent combines multiple detection targets (proteins and mRNAs) into a single diagnostic system. By simultaneously detecting multiple cancer-related markers including but not limited to PSA, the invention maintains broad screening coverage while improving diagnostic accuracy through multi-parameter assessment, reducing both false positives and false negatives
Solution Approach 2:
The patent creates a multi-functional diagnostic composition that can detect various types of cancer markers (proteins and mRNAs) using a unified detection platform. This universal approach allows the same diagnostic system to screen for multiple cancer types and markers, maintaining high screening coverage while achieving superior diagnostic precision through diverse target detection
Data Source
AI summary
The present invention pertains to a multiple biomarker for cancer diagnosis and a use thereof and, specifically, to a composition for cancer diagnosis, comprising an agent for measuring the protein or mRNA expression levels of IGFI, KLK2, PKCα, and TRPM8. The present inventors confirmed that rapid and accurate cancer diagnosis can be performed by detecting the unique marker combination of IGFI, KLK2, PKCα, and TRPM8 of the present invention in serum samples from actual cancer patients and one or more cancers can be simultaneously detected. Thus, the combination of IGFI, KLK2, PKCα, and TRPM8 is expected to allow for the rapid and accurate diagnosis of various cancers including prostate cancer.